ArticleFASEB bioAdvances2025
Doxorubicin Impairs Skeletal Muscle Regeneration by Dysregulating the Early Inflammatory Response.
Article in FASEB bioAdvances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Doxorubicin Impairs Skeletal Muscle Regeneration by Dysregulating the Early Inflammatory Response.FASEB bioAdvances · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
For patients with certain types of malignant tumors, chemotherapy is administered before and/or after surgery. However, the potential impact of chemotherapeutic agents on tissue regeneration and wound healing after surgery is not fully understood. In this study, we examined the possible effects of doxorubicin (DOX), one of the most widely used chemotherapeutic agents, on muscle regeneration using a mouse muscle injury model. Histologic analysis revealed that DOX significantly impairs muscle regeneration, resulting in reduced muscle mass and fibrosis when administered during the early phase of the inflammatory response following injury. Contrary to our initial assumption, DOX administration did not suppress the proliferation of satellite cells or the expression of myogenic transcripts. Rather, DOX delayed the infiltration of immune cells to the injury site, which most likely resulted in insufficient clearance of necrotic tissues and prolonged immune cell infiltration. Taken together, our findings reveal an unrecognized effect of DOX on muscle regeneration and underscore the critical role of the early inflammatory response in initiating proper muscle regeneration after injury.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.